Cutaneous adverse events in chronic hepatitis c patients treated with new direct-Acting antivirals: A systematic review and meta-Analysis

Parth Patel, Kunal Malik, Karthik Krishnamurthy

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Background: Direct-Acting antivirals (DAAs) are known to present with additional dermatological events over pegylatedinterferon/ ribavirin (Peg-IFN/RBV). Objective: A systematic review and meta-Analysis was conducted to assess the incidence/risk of cutaneous adverse events (AEs) for simeprevir, sofosbuvir, ABT450/r-ombitasvir, dasabuvir, ledipasvir, daclatasvir, and asunaprevir. Methods: The databases searched included PubMed, Clinicaltrials.gov, and Clinicaloptions.com. Data on telaprevir and boceprevir were obtained from a previous study. Results: The incidences of cutaneous AEs were 34.3% (95% CI 18.4%-54.8%) for the old DAAs + Peg-IFN/RBV, 22.0% (95% CI 17.9%-26.8%) for the new DAAs + Peg-IFN/RBV, 9.8% (95% CI 8.6%-11.2%) for the DAAs + RBV, and 3.8% (95% CI 2.4%-6.1%) for DAAs only. Simeprevir + Peg-IFN/RBV was associated with an increased relative risk over Peg-IFN/RBV; RR = 1.319 (95% CI 1.026-1.697). Conclusion: Dermatological events are still an important issue for many of the new DAAs. Appropriate monitoring, management, and patient education are needed to minimize AEs and achieve HCV cure.

Original languageEnglish
Pages (from-to)58-66
Number of pages9
JournalJournal of Cutaneous Medicine and Surgery
Volume20
Issue number1
DOIs
StatePublished - 1 Jan 2016
Externally publishedYes

Keywords

  • Dermatitis
  • Dermatology
  • Immunology
  • Infectious Disease

Fingerprint

Dive into the research topics of 'Cutaneous adverse events in chronic hepatitis c patients treated with new direct-Acting antivirals: A systematic review and meta-Analysis'. Together they form a unique fingerprint.

Cite this